|
[1]
|
Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR − 9):1 − 35. |
|
[2]
|
Lai XZ, Wahl B, Yu WZ, Xu TT, Zhang HJ, Garcia C, et al. National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children in China: Modelled estimates for 2010-17. Lancet Reg Health West Pac 2022;22:100430. http://dx.doi.org/10.1016/j.lanwpc.2022.100430CrossRef
|
|
[3]
|
World Health Organization. Pneumococcal conjugate vaccines: WHO position paper. 2019. https://www.who.int/publications-detail-redirect/10665-310968. [2023-3-6].https://www.who.int/publications-detail-redirect/10665-310968 |
|
[4]
|
Chen C, Liceras FC, Flasche S, Sidharta S, Yoong J, Sundaram N, et al. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health 2019;7(1):e58 − 67. http://dx.doi.org/10.1016/S2214-109X(18)30422-4CrossRef
|
|
[5]
|
World Health Organization. Introduction of PCV (Pneumococcal conjugate vaccine). 2022. https://immunizationdata.who.int/pages/vaccine-intro-by-antigen/pneumo_conj.html?ISO_3_CODE=CHN+BRA&YEAR=. [2023-3-6].https://immunizationdata.who.int/pages/vaccine-intro-by-antigen/pneumo_conj.html?ISO_3_CODE=CHN+BRA&YEAR= |
|
[6]
|
Wang J, Wu QS, Lu J, Ni YH, Zhou F. Low vaccination coverage of pneumococcal conjugate vaccines (PCVs) in Shanghai, China: a database analysis based on birth cohorts from 2012 to 2020. Vaccine 2021;39(42):6189 − 94. http://dx.doi.org/10.1016/j.vaccine.2021.09.011CrossRef
|
|
[7]
|
World Health Organization. Pneumococcal vaccination coverage. 2022. https://immunizationdata.who.int/pages/coverage/pcv.html?GROUP=WHO_REGIONS&ANTIGEN=PCV3&YEAR=&CODE=. [2023-3-6].https://immunizationdata.who.int/pages/coverage/pcv.html?GROUP=WHO_REGIONS&ANTIGEN=PCV3&YEAR=&CODE= |
|
[8]
|
GOV.UK. The complete routine immunisation schedule from February 2022. 2022. https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule/the-complete-routine-immunisation-schedule-from-february-2022. [2023-3-6].https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule/the-complete-routine-immunisation-schedule-from-february-2022 |
|
[9]
|
Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006-2018. Vaccine 2019;37(32):4491 − 8. http://dx.doi.org/10.1016/j.vaccine.2019.06.071CrossRef
|
|
[10]
|
Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, et al. Long-term impact of a "3 + 0" schedule for 7- and 13-valent pneumococcal conjugate Vaccines on invasive pneumococcal disease in Australia, 2002-2014. Clin Infect Dis 2017;64(2):175 − 83. http://dx.doi.org/10.1093/cid/ciw720CrossRef
|
|
[11]
|
Du YZ, Wang Y, Zhang T, Ma LB, Xie SY, Wang Y, et al. Factors associated with PCV13 vaccine hesitancy in parents under an innovative immunization strategy: a cross-sectional study — Weifang city, Shandong province, China, 2021. China CDC Wkly 2023;5(12):271 − 7. http://dx.doi.org/10.46234/ccdcw2023.049CrossRef
|
|
[12]
|
Shen KL, Wasserman M, Liu DD, Yang YH, Yang JF, Guzauskas GF, et al. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS One 2018;13(7):e0201245. http://dx.doi.org/10.1371/journal.pone.0201245CrossRef
|